A Comprehensive Review of Pacritinib in Myelofibrosis

Overview

Journal Future Oncol

Specialty Oncology

Date 2015 Sep 15

PMID 26367195

Citations 13

Authors

Srdan Verstovsek

Rami S Komrokji

Affiliations

Soon will be listed here.

Abstract

The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis. However, the association of ruxolitinib therapy with myelosuppression indicates the continued need for optimal treatment choices in myelofibrosis. Pacritinib, a dual JAK2 and FLT3 inhibitor, improves disease-related symptoms and signs with manageable gastrointestinal toxicity in patients with myelofibrosis with splenomegaly and high-risk features, without causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis. This article examines the role of JAK2 and FLT3 signaling in myelofibrosis and provides an overview of the clinical development of pacritinib as a new therapy for myelofibrosis.

Citing Articles

Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib-A Real-Life Longitudinal Study.

Stoeva V, Mihaylov G, Mitov K, Petrova G, Tachkov K Cancers (Basel). 2023; 15(20).

PMID: 37894452 PMC: 10605047. DOI: 10.3390/cancers15205085.

FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis.

Tiz D, Bagnoli L, Rosati O, Marini F, Santi C, Sancineto L Pharmaceutics. 2022; 14(11).

PMID: 36432728 PMC: 9695118. DOI: 10.3390/pharmaceutics14112538.

Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?.

Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette P, Jacobsohn K Cancers (Basel). 2021; 13(20).

PMID: 34680353 PMC: 8533841. DOI: 10.3390/cancers13205204.

Early and late stage MPN patients show distinct gene expression profiles in CD34 cells.

Baumeister J, Maie T, Chatain N, Gan L, Weinbergerova B, de Toledo M Ann Hematol. 2021; 100(12):2943-2956.

PMID: 34390367 PMC: 8592960. DOI: 10.1007/s00277-021-04615-8.

The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer.

Dettorre G, Patel M, Gennari A, Pentheroudakis G, Romano E, Cortellini A ESMO Open. 2021; 6(3):100123.

PMID: 33932622 PMC: 8026271. DOI: 10.1016/j.esmoop.2021.100123.

References

Verstovsek S, Hoffman R, Mascarenhas J, Soria J, Bahleda R, McCoon P . A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. 2014; 39(2):157-63. PMC: 11752076. DOI: 10.1016/j.leukres.2014.11.018. View

Tefferi A . Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88(2):141-50. DOI: 10.1002/ajh.23384. View

Gabler K, Behrmann I, Haan C . JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT. 2013; 2(3):e25025. PMC: 3772115. DOI: 10.4161/jkst.25025. View

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S . Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011; 10(2):127-40. DOI: 10.1038/nrd3264. View

Pardanani A, Laborde R, Lasho T, Finke C, Begna K, Al-Kali A . Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013; 27(6):1322-7. PMC: 3677140. DOI: 10.1038/leu.2013.71. View

Geyer H, Mesa R . Therapy for myeloproliferative neoplasms: when, which agent, and how?. Hematology Am Soc Hematol Educ Program. 2015; 2014(1):277-86. DOI: 10.1182/asheducation-2014.1.277. View

10.

Mascarenhas J, Hoffman R . Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012; 18(11):3008-14. DOI: 10.1158/1078-0432.CCR-11-3145. View

11.

Hatzimichael E, Tsolas E, Briasoulis E . Profile of pacritinib and its potential in the treatment of hematologic disorders. J Blood Med. 2014; 5:143-52. PMC: 4145824. DOI: 10.2147/JBM.S51253. View

12.

Cervantes F . How I treat myelofibrosis. Blood. 2014; 124(17):2635-42. DOI: 10.1182/blood-2014-07-575373. View

13.

Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A . Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012; 30(33):4161-7. PMC: 5950499. DOI: 10.1200/JCO.2012.42.5223. View

14.

Scherber R, Dueck A, Johansson P, Barbui T, Barosi G, Vannucchi A . The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011; 118(2):401-8. DOI: 10.1182/blood-2011-01-328955. View

15.

Vannucchi A, Kiladjian J, Griesshammer M, Masszi T, Durrant S, Passamonti F . Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5):426-35. PMC: 4358820. DOI: 10.1056/NEJMoa1409002. View

16.

Rodig S, Meraz M, White J, Lampe P, Riley J, Arthur C . Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998; 93(3):373-83. DOI: 10.1016/s0092-8674(00)81166-6. View

17.

Rochman Y, Kashyap M, Robinson G, Sakamoto K, Gomez-Rodriguez J, Wagner K . Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci U S A. 2010; 107(45):19455-60. PMC: 2984176. DOI: 10.1073/pnas.1008271107. View

18.

Nangalia J, Massie C, Baxter E, Nice F, Gundem G, Wedge D . Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405. PMC: 3966280. DOI: 10.1056/NEJMoa1312542. View

19.

Abdelrahman R, Begna K, Al-Kali A, Hogan W, Litzow M, Pardanani A . Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2014; 169(1):77-80. DOI: 10.1111/bjh.13262. View

20.

William A, Lee A, Blanchard S, Poulsen A, Teo E, Nagaraj H . Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3).... J Med Chem. 2011; 54(13):4638-58. DOI: 10.1021/jm200326p. View